retinol binding protein 4Genealiases: MCOPCB10 · RDCCAS
Q-omics provides the consensus-scored RBP4 profile across patient tissues and cancer cell-line models. RBP4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RBP4 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, RBP4 RNA expression shows 14,295 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KICH, and TGCT as cancer lineages where RBP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBP4 survival associations across molecular data types. RBP4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBP4 RNA expression–survival associations across cancer types. High RBP4 expression shows unfavorable associations in HNSC and BLCA, but favorable associations in MESO, KIRP, LIHC and DLBC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for RBP4 RNA expression.
This table summarizes RBP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RBP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBP4 shows lower tumor expression in KICH, KIRP, LUAD, LUSC and BRCA and higher tumor expression in COAD. The KICH box plot shows higher RBP4 RNA expression in normal versus tumor tissue (log2 FC = −6.957, t-test p < 0.001).
This table shows molecular features associated with RBP4 in patient tissues and cancer cell lines. In patient samples, RBP4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RBP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LIVER.
